Double-Blind Trial of Miglitol in Type 2 Diabetic Patients With Insulin Treatment

This study has been completed.
Sponsor:
Information provided by:
Sanwa Kagaku Kenkyusho Co., Ltd.
ClinicalTrials.gov Identifier:
NCT00213070
First received: September 13, 2005
Last updated: September 20, 2006
Last verified: September 2006

September 13, 2005
September 20, 2006
Not Provided
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00213070 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Double-Blind Trial of Miglitol in Type 2 Diabetic Patients With Insulin Treatment
Not Provided

The purpose of this study is evaluate the clinical efficacy and safety of Miglitol in patients with Type2 Diabetes Mellitus with treated insulin.

Not Provided
Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Type 2 Diabetes Mellitus
Drug: Miglitol
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
Not Provided
Not Provided
Not Provided

Inclusion Criteria:

  • Type2 diabetes
  • Criteria of postprandial plasma glucose and HbA1c are met

Exclusion Criteria:

  • Type1 diabetes
  • Patients with antidiabetic drugs
  • The other exclusion criteria are met
Both
20 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Japan
 
NCT00213070
MG1005
Not Provided
Not Provided
Sanwa Kagaku Kenkyusho Co., Ltd.
Not Provided
Study Director: Clinical Promotion Group Sanwa Kagaku Kenkyusho Co., Ltd.
Sanwa Kagaku Kenkyusho Co., Ltd.
September 2006

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP